Lilly to build $3 billion oral medicine facility in Netherlands
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
With over two decades of extensive experience, Lal has established himself as a transformational leader in the FMCG and consumer goods sectors
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
Subscribe To Our Newsletter & Stay Updated